MENU

Why the Zelda Therapeutics Ltd share price has surged higher today

Dried marijuana and green capsules.

Although the market has dropped lower for a third day in a row, that hasn’t stopped the Zelda Therapeutics Ltd (ASX: ZLD) share price from jumping higher today.

The pot stock has climbed over 4% to 12.5 cents after announcing plans to expand its clinical trial programme in Chile. As well as insomnia and eczema, the company’s clinical trial will now include autism.

According to the release the company will work with Chilean non-profit patient advocate group Fundación Daya, leveraging its clinical experiences with autism patients.

Pleasingly these clinical experiences have previously demonstrated solid anecdotal evidence of positive quality of life outcomes using cannabinoid-based therapy.

Which I think bodes well for Zelda, especially considering it expects the global market for autism diagnosis and treatments to grow to be worth US$412.7 million by 2019.

Subject to regulatory approvals, trials are expected to commence in the second half of 2017. These trials are expected to last three to six months, meaning Zelda could start generating revenue from Chile and other South American markets as early as 2018.

But is it a buy?

Like fellow pot stock Auscann Group Holdings Ltd (ASX: AC8), I think Zelda has a great deal of potential.

But with a $100 million valuation, the market certainly has factored in a significant amount of growth already.

I feel reasonably confident that AusCann and Zelda are destined to be very successful businesses, but I think the prudent thing to do at this point is to sit on the sidelines and wait to see how its sales develop in 2018.

In the mean time I would suggest investors in search of explosive growth shares check out these hot stocks.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.